Literature DB >> 3582481

Comparative effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of warfarin in man.

S Toon, K J Hopkins, F M Garstang, M Rowland.   

Abstract

Stereochemical aspects of the potential interaction between the oral anticoagulant warfarin and the H2-antagonists, cimetidine and ranitidine, were investigated. A single 25 mg oral dose of racemic warfarin was administered on Day 4 of a randomised 9-day multiple dosing regimen of either cimetidine (800 mg o.d.) ranitidine (300 mg o.d.) or placebo. The degree of anticoagulation produced by warfarin was quantificated by the determination of both the prothrombin and Factor VII clotting times. Ranitidine had no effect on the pharmacodynamics of warfarin or the pharmacokinetics of the individual warfarin enantiomers. Cimetidine whilst producing no statistically significant change in the pharmacodynamics of warfarin or in the pharmacokinetics of the pharmacologically more potent (S) enantiomer, did produce a statistically significant decrease in the clearance of the (R) enantiomer, possibly due to metabolic inhibition of this species.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3582481     DOI: 10.1007/bf00542190

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  24 in total

1.  Behaviour of factors II, VII, IX and X during long-term treatment with coumarin.

Authors:  E A LOELIGER; M J MATTERN; A S den BRABANDER
Journal:  Thromb Diath Haemorrh       Date:  1963-04-15

2.  Interaction of H2-receptor antagonists with drug-metabolizing enzymes.

Authors:  J A Bell; A J Gower; L E Martin; E N Mills; W P Smith
Journal:  Biochem Soc Trans       Date:  1981-02       Impact factor: 5.407

3.  Pharmacokinetic implications of stereoselective changes in plasma-protein binding: warfarin/sulfinpyrazone.

Authors:  S Toon; W F Trager
Journal:  J Pharm Sci       Date:  1984-11       Impact factor: 3.534

4.  Decreased oral warfarin clearance after ranitidine and cimetidine.

Authors:  P V Desmond; M L Mashford; P J Harman; B J Morphett; K J Breen; Y M Wang
Journal:  Clin Pharmacol Ther       Date:  1984-03       Impact factor: 6.875

5.  Cimetidine potentiation of the hypoprothrombinemic effect of warfarin.

Authors:  B A Silver; W R Bell
Journal:  Ann Intern Med       Date:  1979-03       Impact factor: 25.391

6.  Plasma half-lives, plasma metabolites and anticoagulant efficacies of the enantiomers of warfarin in man.

Authors:  D S Hewick; J McEwen
Journal:  J Pharm Pharmacol       Date:  1973-06       Impact factor: 3.765

7.  Lack of effect of ranitidine on warfarin action.

Authors:  M J Serlin; R G Sibeon; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

Review 8.  Cimetidine as an inhibitor of drug metabolism: therapeutic implications and review of the literature.

Authors:  J H Bauman; B J Kimelblatt
Journal:  Drug Intell Clin Pharm       Date:  1982-05

9.  Phenylbutazone-warfarin interaction in man: further stereochemical and metabolic considerations.

Authors:  C Banfield; R O'Reilly; E Chan; M Rowland
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

10.  Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man.

Authors:  A Somogyi; F Bochner
Journal:  Br J Clin Pharmacol       Date:  1984-08       Impact factor: 4.335

View more
  19 in total

1.  The synthetic pentasaccharide fondaparinux sodium does not interact with oral warfarin.

Authors:  Richard A Faaij; Jacobus Burggraaf; Rik C Schoemaker; Rik de Greef; Adam F Cohen
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Absence of an interaction between the synthetic pentasaccharide fondaparinux and oral warfarin.

Authors:  R A Faaij; J Burggraaf; R C Schoemaker; R G M Van Amsterdam; A F Cohen
Journal:  Br J Clin Pharmacol       Date:  2002-09       Impact factor: 4.335

Review 3.  Clinical relevance of cimetidine drug interactions.

Authors:  A F Shinn
Journal:  Drug Saf       Date:  1992 Jul-Aug       Impact factor: 5.606

Review 4.  Stereoselectivity in clinical pharmacokinetics and drug development.

Authors:  D B Campbell
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

Review 5.  Haematological adverse effects of histamine H2-receptor antagonists.

Authors:  J P Aymard; B Aymard; P Netter; B Bannwarth; P Trechot; F Streiff
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Nov-Dec

Review 6.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

7.  Cimetidine-nicoumalone interaction in man: stereochemical considerations.

Authors:  T S Gill; K J Hopkins; J Bottomley; S K Gupta; M Rowland
Journal:  Br J Clin Pharmacol       Date:  1989-04       Impact factor: 4.335

Review 8.  Clinically significant drug interactions with the oral anticoagulants.

Authors:  M D Freedman; A G Olatidoye
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

Review 9.  Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  S M Grant; H D Langtry; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

10.  Further insight into the stereoselective interaction between warfarin and cimetidine in man.

Authors:  I Niopas; S Toon; M Rowland
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.